Skip to Main Content

When it comes to executive compensation in the biotech and pharma sectors, it pays to be CEO of Regeneron Pharmaceuticals.

The company’s chief executive, Len Schleifer, took home $453 million in 2021, more than any other executive in the sector, according to a STAT analysis. That amount represents just less than the entire combined compensation — $478 million — of the next nine highest-paid biotech and pharma CEOs.


Tim Walbert, CEO of Horizon Therapeutics, took home $70 million last year, the second most among biopharma CEOs. Rounding out the top five: BridgeBio Pharma’s Neil Kumar ($63 million), Intellia Therapeutics’ John Leonard ($54 million), and Clay Siegall, the recently departed CEO of Seattle Genetics ($53.5 million).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.